FOR IMMEDIATE RELEASE Christine McCarty 312 596 1617 cmccarty@ziegler.com

## ZIEGLER ADVISES ESSEX MANAGEMENT ON THE SALE TO EMMES

**CHICAGO, IL – APRIL 6, 2023 –** Ziegler, a specialty investment bank, is pleased to announce its role as exclusive financial advisor to Essex Management (Essex) on the sale to Emmes, a global, full-service Clinical Research Organization (CRO) and portfolio company of New Mountain Capital.

Essex provides biomedical informatics and health information technology (HIT) focused consulting services. The company's subject matter experts develop and manage complex health programs for clients in the federal government, private sector and research academia. Like Emmes, Essex shares a successful track record with the National Cancer Institute (NCI). Emmes has provided a range of statistical and data analysis support to NCI since 1978, and Essex has supported NCI since the company's founding in 2009. Essex's bioinformatics technology expertise, combined with Emmes' CRO services, will open doors to new opportunities with a wider set of government agencies and create innovative data strategies for their biopharma clients. Essex's focus on breaking down barriers in clinical research with technology solutions is completely aligned with Emmes' mission and values.

Mark Turco, Managing Director, Ziegler Healthcare Investment Banking stated, "Essex's technical insights allow healthcare stakeholders to make better, data-driven decisions to improve health outcomes. The joint capabilities of Essex and Emmes are compelling, and this partnership will deliver tremendous results for clients going forward. We are thrilled to have represented Essex on this transaction."

Remarking on the transformative potential of the partnership, Essex CEO Kevin Hurley added, "Presenting our complementary service offerings will open new avenues of growth, not only within NCI but with other NIH agencies. Our HIT and bioinformatics depth and Emmes' track record for long, successful partnerships with its public sector clients will make a potent combination. We thank Ziegler for providing valuable strategic and financial advice throughout the sale process."

Ziegler's Healthcare Investment Banking team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.

For more information about Ziegler, please visit us at <a href="http://www.ziegler.com">http://www.ziegler.com</a>.

## About Ziegler:

Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. It has a unique focus on healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory services, fixed income sales, underwriting and trading as well as Ziegler Credit, Surveillance and Analytics. To learn more, visit <a href="http://www.ziegler.com">http://www.ziegler.com</a>.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client's experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.